While NAC helps the body manufacture its own supply, liposomal glutathione provides an immediate boost to the circulating antioxidant pool
In the HERMES experiment, a four-step editing scheme is used, effectively conducting two MEGA-PRESS experiments simultaneously
Given the complex multi-level pathological characteristics of PD, particularly the neurodegenerative changes associated with -syn aggregation, molecular hydrogen, through its selective antioxidant and anti-inflammatory properties, demonstrates multi-target regulatory effects, offering new possibilities for slowing the disease course
Moreover, continuous supplementation is frequently necessary to maintain effects
Semaglutide Wegovy / Ozempic Mechanism: GLP-1 receptor agonist (single target) Weight loss: ~15-17% body weight (STEP trials, 68 weeks) Dosing: Weekly injection, titrated from 0.25mg to 2.4mg Common side effects: Nausea, vomiting, diarrhea, constipation (typically transient) Availability: Longer track record, more widely available Cardiovascular data: SELECT trial demonstrated 20% reduction in major cardiovascular events Tirzepatide Zepbound / Mounjaro Mechanism: Dual GLP-1 + GIP receptor agonist (two targets) Weight loss: ~20-22% body weight (SURMOUNT trials, 72 weeks) Dosing: Weekly injection, titrated from 2.5mg to 15mg Common side effects: Similar GI profile to semaglutide
Liraglutide has resulted in greater HbA 1c and weight reductions in comparison with the other GLP-1 RAs in three clinical trials (Buse et al, 2009
